First Solar stock tanked on June 17 alongside leading residential solar stocks such as Sunrun and Enphase Energy. A closer evaluation of First Solar's business model suggests Mr. Market is throwing the baby out with the water. First Solar's unique CdTe thin-film technology provides supply chain resilience and independence from Chinese crystalline silicon, reducing tariff risk.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Transaction in Own Shares 18 June, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 18 June, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 18/06/2025 605,359 £26.8750 £26.5850 £26.6944 LSE GBP 18/06/2025 149,028 £26.8650 £26.5750 £26.6914 Chi-X (CXE) GBP 18/06/2025 98,613 £26.8650 £26.5850 £26.7127 BATS (BXE) GBP 18/06/2025 561,174 €31.6100 €31.2300 …

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

TPC secures key defense contracts in Guam, tapping into $32 billion in military projects to drive long-term Indo-Pacific growth.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

These companies have reduced their share counts the most over the past 10 years

Fluence faces major US headwinds as Project 2025 policies stall renewables, causing a 72% share price drop and plummeting domestic revenues. Global markets, especially EMEA, APAC, and India, are driving Fluence's growth, offsetting US weakness and diversifying its revenue streams. Fluence's technology and manufacturing presence position it to benefit from the global battery storage boom, despite US policy uncertainty.

Korn Ferry (NYSE:KFY) shares are up 8.8% to trade at $72.64 at last glance, after the company reported better-than-expected earnings and revenue for the fiscal fourth quarter.

Steady digital transformation and strong adoption of AI bode well for Computer Software industry participants like INTU, ADBE and PEGA amid broader market volatility.

The executive-search company tops quarterly earnings and revenue expectations.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (“DoubleVerify” or the “Company”)(NYSE: DV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The Vanguard S&P 500 Index ETF provides unhedged currency exposure to the S&P 500 for Canadian investors. Measured in Canadian dollars, VFV is marginally down so far in 2025, trailing the performance of large-cap Canadian stocks. Despite recent underperformance, the S&P 500 still trades at a 25% higher trailing P/E multiple relative to stocks held in the FTSE Canada Domestic Index.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Texas Instruments Inc (NASDAQ:TXN) has announced plans to invest more than $60 billion to expand semiconductor manufacturing in the United States. The investment will fund the construction and expansion of seven semiconductor fabrication plants (fabs) across three major sites in Texas and Utah, including a mega-site in Sherman, Texas, which alone will receive up to $40 billion for four fabs (SM1 to SM4), the company said on Wednesday.

IFF's proactive R&D investments and strategic acquisitions/divestitures position it for long-term growth, especially in high-margin segments and emerging markets. Divesting the pharma segment allows IFF to focus on core businesses, improve operational efficiency, and channel resources into higher-growth, higher-margin areas. Despite recent stagnating revenue growth and risks from input costs and forex, IFF's essential product portfolio and productivity initiatives provide resilience.

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical approach improve confidence in Dyne's ability to deliver safe, effective therapies. Key data catalysts for DYNE-251 and DYNE-101 are expected in late 2025 and H1 2026, with potential accelerated approval submissions by late 2026.